Visual abstract | Replacement of high-dose chemotherapy with blinatumomab in ND pediatric HR B-ALL: Interim findings from the AIEOP-BFM ALL 2017 phase III trial

Although multimodal treatment approaches have resulted in cure rates exceeding 80% in pediatric acute lymphoblastic leukemia (ALL), intensive chemotherapy remains associated with substantial treatment-related toxicity, particularly in patients with high-risk (HR) disease.¹ Reducing chemotherapy exposure while maintaining efficacy is therefore an important treatment goal. Blinatumomab, a CD19-directed bispecific T-cell engager, may offer an alternative treatment option to particularly intensive and toxic chemotherapy regimens for B-cell ALL (B-ALL).^1,2 

Here, we present a visual abstract summarizing the results from the AIEOP-BFM ALL 2017 phase III trial (NCT03643276), assessing the safety and efficacy of replacing high-dose combination chemotherapy with blinatumomab in newly diagnosed (ND) pediatric HR B-ALL.^1,2 Results from the planned interim analysis, presented by Martin Schrappe at the European Hematology Association 2026 Congress, June 11–14, 2026, Stockholm, SE, demonstrated the feasibility of a chemotherapy-sparing approach, with replacement of selected intensive chemotherapy courses by blinatumomab improving efficacy outcomes while reducing treatment-related toxicity in ND pediatric HR B-ALL.² 

This educational resource is independently supported by Amgen. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.